A recent open-label study has shown that the biological agent abatacept lacks clinical efficacy in PBC, possibly because it could not reduce the frequency of terminally differentiated T cells, especially, CD8+T cells (20). This evidence concerns the gene CD8A and primary biliary cholangitis.